溃疡性结肠炎合并肝损伤2例报告
DOI: 10.3969/j.issn.1001-5256.2021.05.038
Two cases of ulcerative colitis with liver injury
-
-
Key words:
- Colitis, Ulcerative /
- Liver Function /
- Cholangitis, Sclerosing
-
表 1 患者肝功能随访变化
时间 ALT (U/L) AST (U/L) ALP (U/L) GGT (U/L) TBil (μmol/L) 2020年1月22日 111 66 1055 659 12.5 2020年2月1日 147 70 999 670 15.1 2020年2月10日 58 32 645 402 14.0 2020年4月16日 43 30 431 188 13.0 2020年7月24日 41 26 308 172 12.2 表 2 患者入出院及随访肝功能变化
时间 ALT (U/L) AST (U/L) ALP (U/L) GGT (U/L) 2020年3月12日(入院) 84 79 77 68 2020年3月24日(出院) 31 39 65 40 2020年5月14日(停药3周) 188 149 65 45 2020年6月18日(恢复治疗) 20 55 57 28 2020年7月15日(减量5-ASA) 55 54 注:5-ASA, 5-氨基水杨酸。 -
[1] Study Group of Inflammatory Bowel Disease, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment in inflammatory bowel disease(2018, Beijing)[J]. Chin J Pract Intern Med, 2018, 38(9): 796-813. DOI: 10.19538/j.nk2018090106.中华医学会消化病学分会炎症性肠病组. 炎症性肠病诊断与治疗的共识意见(2018年, 北京)[J]. 中国实用内科杂志, 2018, 38(9): 796-813. DOI: 10.19538/j.nk2018090106. [2] LYU H, QIAN JM, WANG LH. The systemic manifestations of ulcerative colitis[J]. Chin J Intern Med, 2002, 41(10): 675-677. DOI: 10.3760/j.issn:0578-1426.2002.10.009.吕红, 钱家鸣, 王利华. 溃疡性结肠炎的肠外表现[J]. 中华内科杂志, 2002, 41(10): 675-677. DOI: 10.3760/j.issn:0578-1426.2002.10.009. [3] SHAN CY, ZHANG QQ, XIAO Y, et al. Incidence and risk factor of extraintestinal manifestations in children with inflammatory bowel disease[J]. Chin J Pediatr, 2019, 57(9): 694-699. DOI: 10.3760/cma.j.issn.0578-1310.2019.09.009.单承颜, 张清清, 肖园, 等. 儿童炎症性肠病肠外表现发生率及危险因素[J]. 中华儿科杂志, 2019, 57(9): 694-699. DOI: 10.3760/cma.j.issn.0578-1310.2019.09.009. [4] BOONSTRA K, van ERPECUM KJ, VAN NIEUWKERK KM, et al. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease[J]. Inflamm Bowel Dis, 2012, 18(12): 2270-2276. DOI: 10.1002/ibd.22938. [5] BJÖRNSSON E, OLSSON R, BERGQUIST A, et al. The natural history of small-duct primary sclerosing cholangitis[J]. Gastroenterology, 2008, 134(4): 975-980. DOI: 10.1053/j.gastro.2008.01.042. [6] CHARATCHAROENWITTHAYA P, ANGULO P, ENDERS FB, et al. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis[J]. Hepatology, 2008, 47(1): 133-142. DOI: 10.1002/hep.21960. [7] LEES CW, BARRETT JC, PARKES M, et al. New IBD genetics: common pathways with other diseases[J]. Gut, 2011, 60(12): 1739-1753. DOI: 10.1136/gut.2009.199679. [8] YANG H, QIAN JM. Current status of research on inflammatory bowel disease with special comorbidities[J]. J Clin Hepatol, 2020, 36(7): 1441-1443. DOI: 10.3969/j.issn.1001-5256.2020.07.001.杨红, 钱家鸣. 炎症性肠病合并特殊共患病的研究现状[J]. 临床肝胆病杂志, 2020, 36(7): 1441-1443. DOI: 10.3969/j.issn.1001-5256.2020.07.001. [9] WANG JB. Association between inflammatory bowel disease and chronic liver diseases and related management strategies[J]. J Clin Hepatol, 2020, 36(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2020.07.002.王江滨. 炎症性肠病与慢性肝脏疾病的关系及其管理策略[J]. 临床肝胆病杂志, 2020, 36(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2020.07.002.